Freedom of Information request on the timeline of the isotretinoin review (FOI 22/094)
Published 31 May 2022
© Crown copyright 2022
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-7-february-2022/freedom-of-information-request-on-the-timeline-of-the-isotretinoin-review-foi-22094
FOI 22/094
11th February 2022
Dear
Thank you for your information request, dated 23rd December, where you asked for “Please, can I stay informed on the timeline of the isotretinoin review.
Additionally, until the EWG and CHM versions of reports are publicly available, can I please be provided with their table of contents. I would like to understand the depth of measures that have been taken in order for prompt legal assessment”
We can confirm that the MHRA does hold this data and we intend to publish the report.
As we plan to publish the report, we consider that your request is covered by Section 22 of the Freedom of Information Act (information intended for future publication) and the information you have asked for is therefore exempt from disclosure. Section 22 is a qualified exemption which means we have considered whether there is a greater public interest in releasing the information requested or withholding it. We recognise there is strong interest in seeing this report and accept it should not be withheld.
We will send you a link to the report once they are published.
I hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.
All information available on the review can be found on the Isotretinoin page - https://www.gov.uk/guidance/isotretinoin-an-expert-review-of-suspected-psychiatric-and-sexual-side-effects
Yours sincerely,
MHRA Customer Experience Centre